Zagato et al., 2020 - Google Patents
Endogenous murine microbiota member Faecalibaculum rodentium and its human homologue protect from intestinal tumour growthZagato et al., 2020
View PDF- Document ID
- 11546021463436437601
- Author
- Zagato E
- Pozzi C
- Bertocchi A
- Schioppa T
- Saccheri F
- Guglietta S
- Fosso B
- Melocchi L
- Nizzoli G
- Troisi J
- Marzano M
- Oresta B
- Spadoni I
- Atarashi K
- Carloni S
- Arioli S
- Fornasa G
- Asnicar F
- Segata N
- Guglielmetti S
- Honda K
- Pesole G
- Vermi W
- Penna G
- Rescigno M
- Publication year
- Publication venue
- Nature microbiology
External Links
Snippet
The microbiota has been shown to promote intestinal tumourigenesis, but a possible anti- tumourigenic effect has also been postulated. Here, we demonstrate that changes in the microbiota and mucus composition are concomitant with tumourigenesis. We identified two …
- 241000736262 Microbiota 0 title abstract description 43
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving viable micro-organisms
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zagato et al. | Endogenous murine microbiota member Faecalibaculum rodentium and its human homologue protect from intestinal tumour growth | |
| Yan et al. | Bacteroides uniformis-induced perturbations in colonic microbiota and bile acid levels inhibit TH17 differentiation and ameliorate colitis developments | |
| Li et al. | Carnobacterium maltaromaticum boosts intestinal vitamin D production to suppress colorectal cancer in female mice | |
| Martin et al. | Bladder cancer, inflammageing and microbiomes | |
| Yu et al. | Gut microbiota modulate CD8+ T cell immunity in gastric cancer through Butyrate/GPR109A/HOPX | |
| Fujiwara et al. | Microbial metabolite sensor GPR43 controls severity of experimental GVHD | |
| Chen et al. | Dietary palmitoleic acid reprograms gut microbiota and improves biological therapy against colitis | |
| Aykut et al. | The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL | |
| Mao et al. | Hyaluronan-induced alterations of the gut microbiome protects mice against Citrobacter rodentium infection and intestinal inflammation | |
| Ren et al. | Gut microbiome affects the response to immunotherapy in non‐small cell lung cancer | |
| Zanoni et al. | CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT activation | |
| Peuker et al. | Epithelial calcineurin controls microbiota-dependent intestinal tumor development | |
| Fan et al. | Activation of HIF-1α and LL-37 by commensal bacteria inhibits Candida albicans colonization | |
| He et al. | Annexin A2 modulates ROS and impacts inflammatory response via IL-17 signaling in polymicrobial sepsis mice | |
| Yan et al. | miRNA-495 suppresses proliferation and migration of colorectal cancer cells by targeting FAM83D | |
| Valeri et al. | Pathogenic E. coli exploits SslE mucinase activity to translocate through the mucosal barrier and get access to host cells | |
| Lu et al. | Consistent activation of the β-catenin pathway by Salmonella type-three secretion effector protein AvrA in chronically infected intestine | |
| Peña-Cearra et al. | Akkermansia muciniphila-induced trained immune phenotype increases bacterial intracellular survival and attenuates inflammation | |
| Marelli et al. | Heme-oxygenase-1 production by intestinal CX3CR1+ macrophages helps to resolve inflammation and prevents carcinogenesis | |
| Liu et al. | The expression of hBDs in the gingival tissue and keratinocytes from healthy subjects and periodontitis patients | |
| Jala et al. | Leukotriene B4-receptor-1 mediated host response shapes gut microbiota and controls colon tumor progression | |
| Li et al. | Curcumin suppresses the progression of gastric cancer by regulating circ_0056618/miR-194-5p axis | |
| Zhang et al. | Faecalibacterium prausnitzii prevents age-related heart failure by suppressing ferroptosis in cardiomyocytes through butyrate-mediated LCN2 regulation | |
| Wu et al. | Gut microbiota-driven metabolic alterations reveal the distinct pathogenicity of chemotherapy-induced cachexia in gastric cancer | |
| Li et al. | Itaconate inhibits SYK through alkylation and suppresses inflammation against hvKP induced intestinal dysbiosis |